Kevin Judice, DICE Therapeutics CEO
October 11, 2022 11:06 AM EDTUpdated October 12, 09:21 AM
R&D

Up­dat­ed: DICE rolls on as lead oral IL-17 can­di­date meets proof-of-con­cept in PhI tri­al, send­ing shares high­er

Paul Schloesser

Associate Editor

DICE Ther­a­peu­tics is now mov­ing for­ward on the next stage of clin­i­cal de­vel­op­ment for its IL-17 can­di­date, on the heels of tout­ing a Phase I …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times